272. Fibrodysplasia ossificans progressiva Clinical trials / Disease details
Clinical trials : 39 / Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04829773 (ClinicalTrials.gov) | January 3, 2019 | 1/4/2021 | Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | Fibrodysplasia Ossificans Progressiva | Drug: Palovarotene;Drug: midazolam | Clementia Pharmaceuticals Inc. | NULL | Completed | 18 Years | 55 Years | All | 48 | Phase 1 | United States |